Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Jefferies Healthcare Conference Presentation – June 2019
ObsEva Short Report 2018
Press Releases
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
press release
May 31, 2018
Geneva, Switzerland and Boston, MA -May 31, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read moreObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
press release
May 16, 2018
Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results…
Read moreObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
press release
May 8, 2018
Geneva, Switzerland and Boston, MA – May 8, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2023
June 29, 2023
ObsEva Annual General Meeting 2022
May 18, 2022
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
